Congress Asset Management Co. Grows Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Congress Asset Management Co. grew its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 12.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 116,620 shares of the biotechnology company's stock after purchasing an additional 12,856 shares during the quarter. Congress Asset Management Co. owned approximately 0.21% of Repligen worth $16,786,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Champlain Investment Partners LLC raised its stake in shares of Repligen by 149.0% during the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company's stock valued at $211,464,000 after purchasing an additional 850,345 shares during the period. Allspring Global Investments Holdings LLC grew its holdings in Repligen by 79.9% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company's stock valued at $65,395,000 after buying an additional 203,011 shares in the last quarter. DF Dent & Co. Inc. increased its position in shares of Repligen by 31.0% during the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company's stock valued at $87,852,000 after buying an additional 139,615 shares during the period. Two Sigma Advisers LP increased its position in shares of Repligen by 421.9% during the third quarter. Two Sigma Advisers LP now owns 126,300 shares of the biotechnology company's stock valued at $18,796,000 after buying an additional 102,100 shares during the period. Finally, Fred Alger Management LLC lifted its holdings in shares of Repligen by 29.5% in the third quarter. Fred Alger Management LLC now owns 398,554 shares of the biotechnology company's stock worth $59,313,000 after buying an additional 90,831 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

RGEN has been the topic of a number of analyst reports. HC Wainwright decreased their target price on shares of Repligen from $240.00 to $180.00 and set a "buy" rating on the stock in a report on Thursday, January 23rd. Canaccord Genuity Group began coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a "hold" rating and a $165.00 price target for the company. Wolfe Research initiated coverage on Repligen in a research report on Thursday, November 14th. They issued a "peer perform" rating on the stock. TD Cowen assumed coverage on Repligen in a research report on Monday, February 10th. They set a "buy" rating and a $200.00 target price for the company. Finally, Canaccord Genuity Group initiated coverage on Repligen in a report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price target on the stock. Six analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $182.91.

Repligen Price Performance

RGEN traded up $11.94 during midday trading on Thursday, hitting $162.67. The stock had a trading volume of 1,769,309 shares, compared to its average volume of 603,400. The company has a market cap of $9.11 billion, a P/E ratio of -439.64, a price-to-earnings-growth ratio of 4.08 and a beta of 0.99. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $203.13. The business has a fifty day moving average of $155.04 and a 200 day moving average of $148.71. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.41 by $0.03. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. As a group, equities analysts forecast that Repligen Co. will post 1.54 earnings per share for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.